Amicus Therapeutics, Inc. provided earnings guidance for the year 2024. For the full-year 2024, the company anticipates total Galafold revenue growth between 11% and 16% at CER.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.99 USD | -2.54% | -6.72% | -29.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.60% | 3.04B | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024